Obesity medicine did not exist, in any formal, fellowship-trained specialty framework, when Dr. Fatima Cody Stanford was deciding what kind of doctor to become. It exists now, in significant part, because physicians such as Stanford helped establish and advance the field.
She is among the first fellowship-trained obesity medicine physicians in the world, and today she serves as Associate Professor of Medicine and Pediatrics at Harvard Medical School and Massachusetts General Hospital, one of the most highly cited obesity medicine physician-scientists in the field, with more than two hundred peer-reviewed publications to her name.
The Long Education
Dr. Stanford’s academic record reads like a tour of American public leadership training. She earned her BS and MPH from Emory University as an MLK Scholar, her MD from the Medical College of Georgia School of Medicine as a Stoney Scholar, and her MPA from the Harvard Kennedy School of Government as a Zuckerman Fellow in the Harvard Center for Public Leadership, a fellowship she held from July 2014 to May 2015.
She later added an executive MBA from the Quantic School of Business and Technology in 2021, supported by a merit-based scholarship. Upon completing her MPH, she received the Gold Congressional Award, the highest honor Congress bestows upon America’s youth.
Her clinical training began with an Internal Medicine and Pediatrics residency at Palmetto Health in Columbia, South Carolina, from July 2008 to June 2012, followed by an Obesity Medicine and Nutrition Fellowship at Massachusetts General Hospital and Harvard Medical School from July 2012 to June 2015.
Before medicine claimed her fully, she spent time as a health communications fellow at the Centers for Disease Control and Prevention and as a behavioral sciences intern at the American Cancer Society. She also worked as a medical journalist for LiveStrong.com and Demand Studios during her residency years.
A Career Built Inside Two Institutions
Dr. Stanford’s professional home has, for more than a decade, been Harvard Medical School and Massachusetts General Hospital simultaneously. She began as an Instructor of Medicine and Pediatrics in July 2015, was promoted to Assistant Professor in May 2019, and became Associate Professor of Medicine and Pediatrics in December 2021, a title she has now held for nearly five years.
Within that same window, she has served in leadership roles at the Nutrition Obesity Research Center at Harvard (NORCH), including Director of Scholarly Engagement and Mentoring and Director of Diversity, as well as founding Co-Director of the Diversity Scholars program.
At MGH specifically, she has served as an Obesity Medicine Physician since July 2015 and has directed External Consultative Care since November 2019. She has also held senior equity and engagement leadership roles within the Endocrine Division and the Department of Medicine. Earlier in her career, she taught Harvard medical students directly, tutoring the Health Care Policy course and the Introduction to Clinical Nutrition course.
A Presence on the National Stage
What sets Dr. Stanford apart, even among prominent academic physicians, is the sheer breadth of institutional bodies that have sought her judgment. She joined the Board of Directors of EOLO Pharma in late 2025, and serves on L’Oréal’s Board of Advisors. She has advised Amgen since March 2024, Apnimed since May 2024, DOX Health since December 2022, and Sweetch, the Tel Aviv-based AI and behavioral platform, since August 2022.
Her pharmaceutical advisory relationships also include Eli Lilly and Company and Currax Pharmaceuticals, both since January 2021, and Boehringer Ingelheim, also since January 2021. Her ties to Novo Nordisk stretch back to January 2016.
She has chaired the communications function for the Obesity Section of the American Academy of Pediatrics, and her broader professional portfolio has included advisory roles with organizations such as Calibrate and the National Institutes of Health Loan Repayment Program. Since July 2013, she has served as a Section Editor for Obesity and Diversity, Equity and Inclusion content at DynaMed, where her work contributes to clinician-facing evidence resources.
Her past service is just as dense. She served on the Board of Directors of The Obesity Society, including as its Advocacy/Regulatory representative in 2023, was a Senior Diversity, Equity and Inclusion Advisor to the NIH, and served as a Board Advisor to GoodRx. In 2022, she was selected as one of the National Academy of Medicine’s Scholars in Diagnostic Excellence, participating in the 2022–2023 program. She advised Pfizer and sat on the Scientific Advisory Board of Rhythm Pharmaceuticals, among other industry and academic appointments.
Within the American Medical Association, Dr. Stanford chaired the Minority Affairs Section from July 2020 to June 2021, having served on its Governing Council since June 2016 and as its Vice Chair from June 2019 to June 2020. She also served on the American Heart Association board from 2020 to 2021 and advised Zimmer Biomet from January 2018 to December 2020.
Within the Massachusetts Medical Society, she chaired the Nutrition and Physical Activity Committee from July 2018 to July 2020 and served as Vice Chair of its Young Physicians Section the year before that. She sat on the Academic Advisory Board of the American College of Physicians from January 2017 to July 2019 and co-chaired The Obesity Society’s Advocacy Committee from July 2016 to June 2019. Internationally, she served as Socio-Medical Affairs Officer for the World Medical Association’s Junior Doctor Network in France from July 2013 to June 2014.
The Honors, in Order
The recognitions accumulated steadily across two decades: the AMA Foundation Leadership Award in 2005, the AMA Paul Ambrose Award in 2009, the ACP Joseph E. Johnson Leadership Award in 2013, the AMA Inspirational Physician Award and the Massachusetts ACP Young Leadership Award, both in 2015, the HMS Amos Diversity Award and the Massachusetts Medical Society Award for Women’s Health in 2017, the Suffolk District Community Clinician of the Year Award in 2019, The Obesity Society’s Clinician of the Year in 2020, and in 2021 alone, both the MMS Grant Rodkey Award and the AMA Dr. Edmond and Rima Cabbabe Dedication to the Profession Award, as well as the Emory Rollins School of Public Health Distinguished Alumni Award.
Dr. Stanford’s later distinctions include selection as a 2022 National Academy of Medicine Scholar in Diagnostic Excellence and recognition by the National Medical Association with its 2024 Meritorious Award.
What emerges is not simply a long resume. It is the record of a physician who decided, early and deliberately, that treating obesity would require sitting in rooms far beyond the exam room, from pharmaceutical boardrooms to policy and professional leadership forums, and who has spent every year since making sure obesity medicine has a seat at each one.
